Table 2 The left part of the table summarizes results from the screening stage for differentially expressed mRNAs over time using microarrays.

From: Persistent mRNA and miRNA expression changes in irradiated baboons

screening with microarray

validation with qRT-PCR

agreement screening/validation

probe name

Gene Symbol

Description

mean differential gene expression over time (d)

TaqMan Assay ID

mean diff. gene expression over time (d)

p-values per day

7

28

75–106

7

28

75–106

7

28

75–106

A_33_P3514487

VSTM1

V-set and transmembrane domain containing 1

0,2

0,3

0,2

Hs00419073_m1

       

A_32_P524614

C17orf74

chromosome 17 open reading frame 74

0,3

0,3

0,3

Hs00545612_s1

       

A_23_P72584

ACBD7

acyl-CoA binding domain containing 7

0,3

0,3

0,2

Hs00744676_s1

       

A_33_P3341787

IDS

iduronate 2-sulfatase

0,4

0,5

0,5

Hs00240821_m1

0,9

0,6

1,3

0,3

0,1

0,2

not

A_33_P3671378

CERCAM

cerebral endothelial cell adhesion molecule

0,4

0,4

0,3

Hs00170969_m1

       

A_23_P251043

SYNDIG1

synapse differentiation inducing 1

0,3

0,3

 

Hs00227616_m1

1,1

0,3

1,1

0,8

0,04

0,7

partly

A_33_P3285734

FCRL6

Fc receptor-like 6

0,3

0,4

 

Hs02341772_m1

0,6

0,5

1,2

0,3

0,4

0,6

not

A_24_P162373

ZNRF3

zinc and ring finger 3

0,4

0,4

 

Hs00393094_m1

       

A_23_P8913

CA2

carbonic anhydrase II

4,7

3,0

 

Hs01070108_m1

2,2

3,1

1,0

0,07

<0.0001

0,9

complete

A_23_P37994

TP53TG3

TP53 target 3

4,0

2,7

 

Hs00414226_g1

       

A_23_P204016

CACNB3

calcium channel, voltage-dependent, beta 3 subunit

3,5

3,2

 

Hs00893804_g1

0,3

0,4

1,1

0,002

0,02

0,74

inverse

A_33_P3249259

TGM6

transglutaminase 6

3,1

2,2

 

Hs00975389_m1

       

A_33_P3815935

TMEM50B

RST40456 Athersys RAGE Library

2,9

2,4

 

Hs00272046_m1

0,8

0,5

1,3

0,6

0,04

0,2

inverse

A_32_P147078

SLC8A1

solute carrier family 8 (sodium/calcium exchanger), member 1

2,8

2,5

 

Hs00253432_m1

       

A_23_P351837

KLHL35

kelch-like 35

2,7

2,6

 

Hs00400533_m1

       

A_19_P00805942

SLC7A14

solute carrier family 7, member 14

2,7

2,2

 

Hs00703486_s1

       

A_33_P3213512

COQ5

coenzyme Q5 homolog, methyltransferase

2,7

2,2

 

Hs00260456_m1

 

0,7

1,0

 

0,1

0,9

not

A_23_P17811

SEC. 14L2

SEC. 14-like 2

2,6

2,1

 

Hs01052193_g1

       

A_23_P60517

FXN

frataxin (FXN), nuclear gene encoding mitochondrial protein

2,6

2,7

 

Hs00175940_m1

       

A_23_P166526

RIBC2

RIB43A domain with coiled-coils 2

2,5

2,5

 

Hs00210331_m1

       

A_23_P75038

DCLRE1A

DNA cross-link repair 1 A

2,3

2,6

 

Hs00384872_m1

       

A_33_P3294017

HNRNPC

heterogeneous nuclear ribonucleoprotein C (C1/C2)

 

3,7

3,8

Hs01028910_g1

0,8

0,3

1,0

0,2

0,0095

0,9

inverse

A_23_P251647

RFESD

Rieske (Fe-S) domain containing

 

2,7

2,1

Hs00379296_m1

       

A_33_P3260605

CTNNAL1

catenin (cadherin-associated protein), alpha-like 1

 

2,7

2,2

Hs00169384_m1

       

A_24_P346126

SERF1A

small EDRK-rich factor 1A (telomeric)

 

2,6

2,6

Hs00743093_s1

       

A_33_P3229122

HIST1H2BF

histone cluster 1, H2bf

 

2,3

2,1

Hs00371409_s1

       

A_33_P3256303

SELPLG

selectin P ligand

 

0,3

0,5

Hs00380945_m1

1,1

0,4

1,1

0,8

0,02

0,6

partly

A_23_P50919

SERPINE2

serpin peptidase inhibitor, clade E

 

0,4

0,4

Hs00299953_m1

       

A_33_P3461633

LOC284454

uncharacterized LOC284454, non-coding RNA

 

0,5

0,3

Hs01065212_s1

0,4

0,2

1,2

0,3

0,006

0,7

partly

A_24_P228550

TUBB1

tubulin, beta 1 class VI

 

0,5

0,3

Hs00258236_m1

1,6

0,6

1,0

0,3

0,2

0,9

not

A_23_P47410

ESAM

endothelial cell adhesion molecule

 

0,5

0,4

Hs00332781_m1

2,2

0,6

1,0

0,04

0,2

0,8

partly

A_23_P74114

ZNF713

zinc finger protein 713

 

0,5

0,4

Hs00403582_m1

       
  1. The right part of the table shows the results from the validation stage. In total 32 candidate genes from screening were validated employing a specific primer-probe design (TaqMan Assay ID). Differential gene expression (fold changes relative to unexposed controls) and corresponding p-values are shown per day for each mRNAs where amplification plots were developed in ≥60% of the examined samples. Fold-changes in gene expression and associated p-values that showed successful validation are shown in bold letters. The last column summarizes the agreement between screening and validation results. A complete agreement reflects an up- or down-regulation in the same direction in both stages over e.g. several days and a partial agreement refers to a validation of e.g. only changes in gene expression of one and not all days differentially expressed during the screening stage. An inverse agreement represents significant changes in gene expression in one direction (e.g. up-regulated) during the screening and an opposite significant regulation (e.g. down-regulated) during the validation stage.
Back to article page